3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
13
Genitourinary
2
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Leiomyosarcoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Breast Neoplasms
1
Interventions
Paclitaxel
3
aflibercept
2
Taxes
2
Specimen Handling
2
Psychiatric Rehabilitation
2
Magnetic Resonance Spectroscopy
2
Gene Expression Profiling
2
Fentanyl
2
Cisplatin
2
Carboplatin
2
tinostamustine
1
sodium thiosulfate
1
rucaparib
1
pelcitoclax
1
motexafin lutetium
1
entinostat
1
cobimetinib
1
X-Rays
1
Topotecan
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Serotonin Plasma Membrane Transport Proteins
1
Ropivacaine
1
Radiotherapy
1
Radiation
1
Quality of Life
1
Polymerase Chain Reaction
1
Platinum
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
rucaparib
×
Sarcoma
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts